Browse

You are looking at 301 - 350 of 1,314 items for :

  • Clinical Resources x
  • Refine by Access: All content x
Clear All
Restricted access

Dapsone Suspension 2 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Dapsone Suspension 2 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Dapsone Syrup 2 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Free access

1 Definitions and Concepts

Karen J. Tietze

Restricted access

Dexamethasone Suspension 1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Diazoxide Suspension 10 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Diazoxide Suspension 10 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Diclofenac Sodium Suspension 5 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

13 DIGOXIN

Robert J. DiDomenico and II Robert L. Page

Restricted access

CH 1.7 Digoxin

John E. Murphy

Restricted access

CH 2.7 Digoxin

John E. Murphy

Restricted access

Diltiazem Hydrochloride Suspension 12 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Diltiazem Suspension 12 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Dipyridamole Suspension 10 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Dipyridamole Suspension 10 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Disopyramide Syrup 1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Disopyramide Syrup 10 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Dolasetron Mesylate Suspension 10 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

6 DRUG DOSING IN PEDIATRIC PATIENTS

Vinita B. Pai and Milap C. Nahata

Restricted access

22 Drug Screens and Toxicological Tests

Peter A. Chyka

Restricted access

11 Electrolytes, Other Minerals, and Trace Elements

Lingtak-Neander Chan and Jasmine S. Mangrum

Restricted access

Enalapril Maleate Suspension 0.1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Enalapril Maleate Suspension 1 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Enalapril Maleate Suspension 1 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Enalapril Maleate Suspension 1 mg/mL—Formulation 3

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

9 Endocrine Disorders

Eva Vivian

Restricted access

Erlotinib Suspension 10 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Eslicarbazepine Acetate Suspension 40 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

CH 1.3 Estimating Kidney Function

John E. Murphy

Restricted access

CH 2.3 Estimating Kidney Function

John E. Murphy

Restricted access

Ethacrynic Acid Solution 1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

14 ETHOSUXIMIDE

Jacquelyn L. Bainbridge, Pei Shieen Wong, Sarah N. Rajkovic, and Grace S. Chin

Restricted access

Etoposide Solution 10 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access
Cover Extemporaneous Formulations

Extemporaneous Formulations

for Pediatric, Geriatric, and Special Needs Patients

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Famotidine Suspension 8 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Famotidine Syrup 8 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Flecainide Acetate Suspension 20 mg/mL—Formulation 1*

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Flecainide Acetate Suspension 20 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Fluconazole Solution 1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Flucytosine Suspension 10 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Flucytosine Suspension 50 mg/mL*

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Fluoxetine Hydrochloride Syrup 1 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Fluoxetine Hydrochloride Syrup 2 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Furosemide Suspension 2 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Furosemide Suspension 9.6 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Gabapentin Suspension 100 mg/mL—Formulation 1

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Gabapentin Suspension 100 mg/mL—Formulation 2

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Gabapentin Suspension 50 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Restricted access

Ganciclovir Intravitreous Solution 20 mg/mL

Rita K. Jew, Winson Soo-Hoo, Elham Amiri, and Jamie M. Gomes

Free access

CH 1.1 General Pharma­cokinetic Applications

John E. Murphy